Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

Senior Executives Highlight Mergers and Acquisitions and Expansions at DCAT Week ’18

At the DCAT Member Company Announcement Forum, held during DCAT Week, senior executives from member companies of the Drug, Chemical & Associated Technologies Association (DCAT) provided the latest major news from their companies impacting the pharmaceutical manufacturing value chain. So what did they report?

The executives highlighted key strategic activity, including mergers and acquisitions (M&A), post-M&A integration, and manufacturing expansions. Lonza, DowDuPont, Catalent, Novasep, CordenPharma, Piramal Pharma Solutions, SK biotek, Biocon, Procos, Nosco, AB BioTechnologies, and PolyCrystalLine were among the companies taking the podium to provide their latest developments.

The executives highlighted developments to expand active pharmaceutical ingredient (API) development and manufacturing (both small molecules and biologics), drug-product development and manufacturing (both solid dosage and parenteral drugs), and packaging. A roundup of these developments are provided in the stories below.

Lonza Updates Integration of $5.5-Billion Acquisition of Capsugel

DowDuPont Outlines Integration of Combined Company, Including Excipients Business

Catalent Updates Integration of $950-Million Acquisition of Cook Pharmica

Novasep Announces $65-Million Investment in Biologics

CordenPharma Outlines Integration of Former Pfizer API Facility

Piramal Pharma Solutions CEO Outlines Expansion Plans

SK biotek Outlines Integration of Former BMS API Manufacturing Facility

Biocon COO Highlights Company’s Growth Strategy

Procos CEO Outlines Expansion for High-Potency Manufacturing

Nosco President Discusses Company’s Growth Strategy in Wake of Two Key Acquisitions

AB BioTechnologies CEO Announces $12-Million Expansion

PolyCrystalLine CEO Announces Expansion of Solid-State Chemistry Capabilities

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

The CDMO/CMO and Suppliers Report: Biomanufacturing

By
Driven by increased demand in biologic-based drugs, biomanufacturing (biologic drug substance) continues to be an active area of investment by CDMOs/CMOs, including several multi-billion large-scale biomanufacturing projects. What companies are expanding and where do these expansions stand?

Drug Shortages on the Rise; US Gov’t Proposes New Actions to Address

By
The number of drug shortages in the US has reached a new all-time high, with more than 320 drugs in shortage, according to an analysis by a pharmacist trade group. Earlier this month, the White House proposed new actions to address the problem, including additional requirements for manufacturers.

Senior Executives Highlight Expansions, M&A at the DCAT Member Company Announcement Forum 

By
Senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week.

DCAT Value Chain Insights Bonus Coverage: From DCAT Week 2024: Supplier News Roundup 

By
What other DCAT Member Companies are making the news? A roundup of the latest developments from CDMOs/CMOs and other suppliers in drug-substance (small molecules & biologics) and drug-product development and manufacturing and packaging.